WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...
WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for JANUVIA(TM) (sitagliptin), the only DPP-4 inhibitor ...
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with ...
Unichem has obtained tentative approval from the Food and Drug Administration for sitagliptin tablets in dosage strengths of 25 mg, 50 mg, and 100 mg The medication is a generic of Merck Sharpe and ...
Adjunct to diet and exercise in type 2 diabetes, as monotherapy or in combination with either metformin or a thiazolidinedione. Incretins, such as glucagonlike peptide-1 (GLP-1) and glucose-dependent ...
Januvia (sitagliptin) is a prescription drug that’s used to treat type 2 diabetes. This drug can interact with other medications. For example, Januvia can interact with other diabetes medications and ...
COPENHAGEN, June 26 (Reuters) - Novo Nordisk said on Saturday extension data from a study showed its new diabetes drug Victoza provided better blood sugar control and also weight reduction than ...
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback